reased systemic exposure of velpatasvir. Velpatasvir is a substrate for the drug transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP); in vitro data show that sapropterin may inhibit these transporters. If these drugs are used together, closely monitor for increased side effects of velpatasvir.
Saquinavir: Use caution when administering velpatasvir with saquinavir. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, saquinavir is a potent inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Simeprevir: Avoid coadministration of sofosbuvir with simeprevir, a P-glycoprotein (P-gp) inhibitor. Taking these drugs together may increase sofosbuvir plasma concentrations, potentially resulting in adverse effects. Use caution when administering velpatasvir with simeprevir. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). Simeprevir also inhibits the Breast Cancer Resistance Protein (BCRP); while velpatasvir is a BCRP substrate.
Simvastatin: Use caution when administering velpatasvir with simvastatin. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). Additionally, velpatasvir is an inhibitor of the organic anion transporting polypeptides OATP1B1 and OATP1B3. Simvastation is an OATP substrate.
Simvastatin; Sitagliptin: Use caution when administering velpatasvir with simvastatin. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). Additionally, velpatasvir is an inhibitor of the organic anion transporting polypeptides OATP1B1 and OATP1B3. Simvastation is an OATP substrate.
Sirolimus: Use caution when administering velpatasvir with sirolimus. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Velpatasvir is a substrate of the Breast Cancer Resistance Protein (BCRP); sirolimus is a potent inhibitor of BCRP. Sirolimus is also a substrate for P-glycoprotein (P-gp); while velpatasvir is a P-gp inhibitor.
Sorafenib: Use caution when administering velpatasvir with sorafenib. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); sorafenib is a weak in vitro inhibitor of P-gp. Sorafenib is also an in vitro inhibitor of the hepatic enzymes CYP3A4, CYP2C8, and CYP2B6. Velpatasvir is a substrate of all three enzymes.
St. John's Wort, Hypericum perforatum: Avoid coadministration of sofosbuvir, a P-glycoprotein (P-gp) substrate with inducers of P-gp, such as St. John's Wort, Hypericum perforatum. Taking these drugs together may significantly decrease sofosbuvir plasma concentration, potentially resulting in loss of antiviral efficacy. Avoid coadministration of velpata |
